期刊文献+

紫杉醇联合吉西他滨治疗晚期复发转移性乳腺癌的临床疗效分析 被引量:4

下载PDF
导出
摘要 目的探讨紫杉醇联合吉西他滨治疗晚期复发转移性乳腺癌的临床疗效。方法选取32例晚期复发转移性乳腺癌患者,均接受紫杉醇联合吉西他滨治疗,观察患者的临床疗效。结果 32例患者中,完全缓解的1例,占3.13%;部分缓解的14例,占43.75%;稳定的12例,占37.5%;疾病进展的5例,占15.63%。有效率为46.88%,疾病控制率为84.38%,中位无进展生存期5.6个月。结论紫杉醇联合吉西他滨治疗晚期复发转移性乳腺癌临床疗效良好好。 Objective Analysis on the efficacy of chemotherapy by Paclitaxel and Gemcitabine in recurrent metastatic breast cance. Methods 32 cases of recurrent metastatic breast cance received Paclitaxel and Gemcitabinc. Results CR 3.13%,PR 43.75%, SD 37.5%,PD 15.63%,RR 46.88%, the median progression-free survival was 5.6 months. Conclusion The combined use of Paclitaxel and Gemcitabine is relatively effective for treatment of patients with metastatic breast cancer.
作者 吕红琼
出处 《当代医学》 2013年第32期150-151,共2页 Contemporary Medicine
关键词 紫杉醇 吉西他滨 转移性乳腺癌 化疗 Paclitaxel Gemcitabine Metastatic-breast cancer Chemotherapy
  • 引文网络
  • 相关文献

参考文献5

  • 1中华人民共和国卫生部医政司.中国常见恶性肿瘤诊治规范(第九册)[M].北京:北京医科大学中国协和医科大学联合出版社,1991:10-15.
  • 2McGurie WP,Eowinsky EK. PacYitaxel in cancer treatment[M]. New York: Mercel Dekker Inc USA, 1995,35-40.
  • 3陈丽荣,郑树,MCWilingham,范伟民.紫杉醇诱发人乳癌细胞凋亡的机制研究[J].中华肿瘤杂志,1997,19(2):103-106. 被引量:82
  • 4郝春芳,江泽飞,宋三泰.紫杉特尔在乳腺癌化疗中的应用[J].国外医学(肿瘤学分册),2003,30(2):129-132. 被引量:37
  • 5Vassilomanolakis M,Koumakls G,Barbounis G,et al.Vinordbine and cisplation in metastatic breast cancer patients previously treated with anthradeclines[J]. Ann Oncol, 2000, 11 (9), 1155-1160.

二级参考文献29

  • 1Ibrahim NK, Rahman Z, Valero V, et al. Phase Ⅰ study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer [J]. Cancer Invest, 2002,20(1): 29-37.
  • 2Venturini M, Del Mastro L, Garrone O, et al. Phase Ⅰ, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer [ J ]. Ann Oncol, 2002,13(4): 546-552.
  • 3Schwetz BA. From the Food and Drug Administration [J]. JAMA,2001,286(17) : 2085.
  • 4O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracyclin-pretreated patients with advanced breast cancer: phase Ⅲ trial results [J]. J Clin Oncol, 2002,20(12): 2812-2823.
  • 5Brugnatelli S, Danova M, De Bella MT, et al. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study [J]. Oncology, 2002,62(1): 33-38.
  • 6Frasci G, Comella P, D' Aiuto G, et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study [J]. Ann Oncol, 2000, 11(3):367-371.
  • 7Burris HA 3rd.Docetaxel (Taxotere) plus trasuzumab (Herceptin) in breast cancer [J]. Semin Oncol, 2001,28(1 Suppl 3) : 38-44.
  • 8Esteva FJ, Valero V, Booser D, et al. Phase I1 study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer [J]. J Clin Oncol, 2002,20(7): 1800-1808.
  • 9Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel [J]. J Clin Oncol, 2002, 20(6): 1456-1466.
  • 10Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant vhemotherapy for stage Ⅱ and Ⅲ Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase Ⅱ , Multicenter Study [J]. Clin Cancer Res, 2003,9(2): 686-692.

共引文献117

同被引文献31

  • 1Silver DP, Richardson AL, Eklund AC, et al. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer[J]. J Clin Oncol, 2010, 28 (7): 1145-1153.
  • 2Mo JI, Eggers PK, Raston CL, et al. Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles[J]. Anal Bioanal Chem, 2014, 27(6): 4562- 4569.
  • 3Yoneyama K, Konishi H, Yahata T, et al. A Phase II Study of Paclitaxel and Carboplatin with a Biweekly Schedule in Patients with Epithelial Ovarian Cancer: Gynecologic Cancer Network Trial [J]. J Nippon Med Sch, 2014, 81(1): 28-34.
  • 4Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective regimen as neoadjuvant chemotherapy for breast cancer[J]. Ann Oncol, 2010, 21(5): 961-967.
  • 5Von Minckwitz G, Untch M, NUesch E, et al. Impact of treatment characteristics on response of different breast cancer pheno types: pooled analysis of the German neo-adjuvant chemotherapy trials [J]. Breast Cancer Res Treat, 2011,125(1): 145-156.
  • 6Pignata S, Scambia G, Katsaros D. Carboplatin plus paelitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial [J]. Lancet Oneol, 2014, 34(5): 1470-1475.
  • 7Suzuki H, Hirashima T, Kobayashi M, et al. Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases [J]. Mol Clin Oncol, 2013, 1 (3): 480-482.
  • 8Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple- negative breast cancer patients [J]. Cancer Chemother Pharmaeol, 2011, 67(4): 911-917.
  • 9Van de Ven S, Smit VT, Dekker TJ, et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer [J]. Cancer Treat Rev, 2011, 37(6): 422-430.
  • 10Sonobe S, Inoue K, Tachibana S, et al. A Case of Pulmonary Mucoepidermoid Carcinoma Responding to Carboplatin and Paclitaxel[J]. Jpn J Clin Oncol, 2014, 13(5): 635-639.

引证文献4

二级引证文献8

;
使用帮助 返回顶部